Guest guest Posted May 24, 2008 Report Share Posted May 24, 2008 While following some links, I found references to RAD 001 and suddenly remembered it was the drug that my " little friend " , whom I met at MDACC was taking for CML. Seems she was the only patient enrolled in the trial. Now it seems they have found other uses for it. I found an article about using it for the treatement of kidney cancer. " THE METHODIST group (in Houston) plans to enroll an additional 40 patients who have failed prior Nexavar or Sutent therapy. " http://www.ackc.org/rad001. There is also a report from ASCO: http://www.ackc.org/asco_2007 " There are now four drugs that are FDA approved for kidney cancer: Nexavar (2005), Sutent (2006), Torisel (2007), and Interleukin-2 (1992). There are also a couple of targeted agent drugs in the pipeline that will likely be approved in 2008. It remains to be seen if the availability of therapies will have an impact on the number of patients who enter clinical trials, where new drugs are developed. Currently only 3% of kidney cancer patients enter clinical trials. " It would seem that they are crossing over with RAD 001 in the treatment of prostate cancer as well. http://clinicaltrials.gov/show/NCT00630344. ' Orally administered inhibitor of mTOR, is also being trialed in the treatment of melonoma. ' Interim analysis after enrollment of 20 patients suggests that RAD-001 is well tolerated and has sufficient anti-tumor activity in MM to warrant the opening of enrollment to the second stage of this trial. Further accrual is planned .Interim analysis after enrollment of 20 patients suggests that RAD-001 is well tolerated and has sufficient anti-tumor activity in MM to warrant the opening of enrollment to the second stage of this trial. Further accrual is planned. " http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?\ vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD & vmview=abst_detail_view & confI\ D=40 & index=y & abstractID=30079 Blessings and peace, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.